AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18272891
Drug: Rituximab (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1000 mg intravenous on days 1 and 15)
Trial: 16204792
Drug: Intranasal histamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal histamine (4 mg/ml, 0.1 ml)
Trial: 16204792
Drug: Intranasal histamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal histamine
Trial: 14576754
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg pyridoxine/day
Trial: 10665894
Drug: Melatonin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (2 mg controlled-release formulation)
Trial: 8717596
Drug: TMP-SMX (160/800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP-SMX (160/800 mg) daily
Trial: 8717596
Drug: Aerosolized pentamidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized pentamidine (300 mg) monthly
Trial: 8390084
Drug: calcium+vitamin D
RxNorm normalized name: Calcium/Cholecalciferol 500 MG-10 MCG Oral Tablet [LEADER CALCIUM+VITAMIN D3]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calcium+vitamin D supplements
Trial: 3443597
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo administration)
Trial: 31674093
Drug: Bioengineered bilayered
RxNorm normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioengineered bilayered living cell construct (BLCC) plus compression therapy
Trial: 31674093
Drug: Compression therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression therapy (control)
Trial: 28574780
Drug: Various interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Various interventions targeting treatment engagement in youth mental health services
Trial: 18568441
Drug: Femal (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femal (160 mg twice-daily for four menstrual cycles)
Trial: 12789181
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with Metvix and 75 J/cm² red light, performed twice weekly for 12 weeks, then once weekly.
Trial: 12789181
Drug: Paromomycin sulfate,
RxNorm normalized name: Paromomycin Sulfate, 250 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paromomycin sulfate, administered once daily.
Trial: 10619534
Drug: Dietary intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary intervention with counseling to adopt a diet containing 28% or less of calories from total fat, <8% saturated fat, up to 9% polyunsaturated fat, and 11% monounsaturated fat, and dietary cholesterol intake of less than 75 mg/1,000 kcal
Trial: 7646090
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (20 ppm x 10 minutes)
Trial: 7646090
Drug: Intravenous prostacyclin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous prostacyclin (20 ng.kg‐1.min‐1 x 10 minutes)
Trial: 28377389
Drug: Prolonged-release tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release tacrolimus suspension administered orally
Trial: 28377389
Drug: Prolonged-release tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release tacrolimus suspension administered via nasogastric tube
Trial: 28377389
Drug: Intact capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact capsules
Trial: 23955148
Drug: NVS123 formulated
RxNorm normalized name: Tarsum Reformulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVS123 formulated as dry filled capsules administered orally with high-fat meal
Trial: 23955148
Drug: Alternative formulations
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative formulations developed and assessed in preclinical and/or clinical studies
Trial: 23955148
Drug: Amorphous formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amorphous formulation of NVS123
Trial: 21563916
Drug: Radioiodine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine therapy (131I) with an administered activity of 1.85-4.07 MBq per gram of thyroid tissue (average 261 ± 162 MBq) in Group 3
Trial: 21563916
Drug: Radioiodine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine therapy (131I) with varying activities in other groups
Trial: 12766641
Drug: Terlipressin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (1 mg intravenous)
Trial: 15504192
Drug: Rocuronium 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.4 mg kg(‐1)
Trial: 15504192
Drug: Succinylcholine 1
RxNorm normalized name: Succinylcholine 124 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 1 mg kg(‐1)
Trial: 9061310
Drug: Unheated cornstarch
RxNorm normalized name: cornstarch
DrugBank: Starch, corn (DB11599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unheated cornstarch (106 g of CHO)
Trial: 9061310
Drug: Mixed equicaloric
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed equicaloric meal (58 g of CHO)
Trial: 9061310
Drug: Smaller mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smaller mixed meal (17 g of CHO)
Trial: 2467137
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg once daily added to captopril 25 mg twice daily for 4 weeks
Trial: 2467137
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to captopril 25 mg twice daily for 4 weeks
Trial: 29775170
Drug: Dose-adjusted warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-adjusted warfarin (INR 2-3)
Trial: 23680036
Drug: MIPS (multi-ingredient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIPS (multi-ingredient performance supplement)
Trial: 8971437
Drug: Picotamide (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picotamide (900 mg day-1)
Trial: 6337405
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of guanabenz twice daily as well as hydrochlorothiazide
Trial: 24648302
Drug: Bioavailability-boosted curcuminoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioavailability-boosted curcuminoids preparation (180 mg/day)
Trial: 21786525
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ketoprofen administered intravenously one hour before the procedure and at 8, 24, 36 and 48 h after
Trial: 21786525
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% saline) administered intravenously one hour before the procedure and at 8, 24, 36 and 48 h after
Trial: 11999818
Drug: Octreotide infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide infusion for 48 hours
Trial: 11999818
Drug: Octreotide infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide infusion for 48 hours plus 72 hours subcutaneous injection
Trial: 8507446
Drug: Octreotide infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide infusion
Trial: 11999818
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of octreotide for another 72 hours
Trial: 29505689
Drug: TENS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TENS treatment
Trial: 3540813
Drug: Placebo TENS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo TENS treatment
Trial: 31331564
Drug: Ranitidine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine plus quince syrup
Trial: 28371141
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy for HFrEF alone
Trial: 19375592
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg daily for 6 months
Trial: 15503074
Drug: Psychosocial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychosocial intervention program (six modules in five weekly group sessions)
Trial: 3430263
Drug: Mineral oil
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineral oil therapy (M)
Trial: 26585287
Drug: LY2940094 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2940094 (40 mg once daily for 8 weeks)
Trial: 23767831
Drug: Aflibercept (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept (administered every 2 weeks)
Trial: 18832884
Drug: Recombinant native
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant native HIV-1 Tat protein vaccine
Trial: 7908147
Drug: Parlodel (bromocriptine)
RxNorm normalized name: bromocriptine Oral Capsule [Parlodel]
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parlodel (bromocriptine) fast titration (15 mg/day for 3 weeks)
Trial: 7908147
Drug: Parlodel (bromocriptine)
RxNorm normalized name: bromocriptine Oral Capsule [Parlodel]
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parlodel (bromocriptine) slow titration (15 mg/day for 5 weeks)
Trial: 3593985
Drug: Tamoxifen (T)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (T) alone or T in combination with medroxyprogesterone acetate, diethylstilbestrol, halotestin, or aminoglutethimide
Trial: 24708917
Drug: Selenium (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium (60 μg/d, as Se-enriched yeast)
Trial: 20555331
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg day(-1) valsartan
Trial: 20555331
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg day(-1) valsartan
Trial: 16759447
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (TCM) including Salvia miltiorrhiza, Acanthopanax senticosus, Ginkgo biloba, Pueraria lobata, Liguisticum chuanxiong, cow bezoar, Diospyros kaki, Gynostemma pentaphyllum
Trial: 12627988
Drug: Nasal budesonide
RxNorm normalized name: budesonide Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal budesonide 128 microg twice daily
Trial: 12627988
Drug: Nasal budesonide
RxNorm normalized name: budesonide Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal budesonide 128 microg twice daily after polypectomy
Trial: 10356887
Drug: Bifidobacterium breve
RxNorm normalized name: Bifidobacterium Breve
DrugBank: Bifidobacterium breve (DB16549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium breve YIT4064, 50 mg daily for 28 days
Trial: 2065844
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cisplatin (50 mg/m2) with short treatment regimen (6 months)
Trial: 2065844
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cisplatin (50 mg/m2) with extended treatment regimen (12 months)
Trial: 2065844
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cisplatin (50 mg/m2) with treatment in blocks (intervening months without cisplatin)
Trial: 2065844
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose cisplatin (100 mg/m2) with short treatment regimen (6 months)
Trial: 2065844
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose cisplatin (100 mg/m2) with extended treatment regimen (12 months)
Trial: 2065844
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose cisplatin (100 mg/m2) with treatment in blocks (intervening months without cisplatin)
Trial: 29666026
Drug: Checkpoint inhibitors
RxNorm normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Checkpoint inhibitors (nivolumab, pembrolizumab, cemiplimab)
Trial: 27682034
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg intravenous)
Trial: 22119935
Drug: levodopa (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levodopa (200 mg) / benserazide (50 mg)
Trial: 25231091
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg peramivir
Trial: 9863850
Drug: Biofeedback‐assisted behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback‐assisted behavioral treatment
Trial: 9863850
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment (oxybutynin chloride, 2.5 mg daily to 5.0 mg 3 times daily)
Trial: 8721904
Drug: All four
RxNorm normalized name: Jackson's The Original All Fours
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All four drugs (rifampicin, isoniazid, pyrazinamide, ethambutol) for younger patients
Trial: 399315
Drug: Nordial (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nordial (combination of ethynyl oestradiol and levonorgestrel)
Trial: 26194186
Drug: Perioperative ECF
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative ECF chemotherapy
Trial: 22873758
Drug: Intramuscular injections
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections of botulinum toxin A (BoNT‐A) combined with standard therapy
Trial: 9839623
Drug: Hyaluronidase as
RxNorm normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hyaluronidase as an additive to chemotherapy and radiation therapy
Trial: 9839623
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and radiation therapy without hyaluronidase
Trial: 7983236
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg dose of loracarbef
Trial: 7983236
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg dose of loracarbef
Trial: 7983236
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg dose of loracarbef (women)
Trial: 7983236
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg dose of loracarbef (women)
Trial: 7983236
Drug: loracarbef (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: loracarbef (400 mg dose)
Trial: 31429629
Drug: Basic gel
RxNorm normalized name: ALCOHOL 67 mL in 100 mL TOPICAL LIQUID [Pacific Blue Basic Gel Hand Sanitizer with Moisturizers]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic gel containing 3%(w/w)-TTO
Trial: 31429629
Drug: Advanced gel
RxNorm normalized name: Walgreens Advanced Gelatin Plus Silica 1080mg Capsule
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Advanced gel containing 3%(w/w)-TTO plus essential oils and vitamins
Trial: 29560955
Drug: Early operative
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early operative treatment (12‐hour medication)
Trial: 29560955
Drug: Long‐term conservative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long‐term conservative treatment (48 hours)
Trial: 27075843
Drug: Weekly surveys
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly surveys
Trial: 25741400
Drug: Cyanoacrylate topical
RxNorm normalized name: 2-octyl cyanoacrylate TOPICAL LIQUID (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyanoacrylate topical adhesive
Trial: 20942668
Drug: Tanezumab (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanezumab (10, 25, 50, 100, or 200 μg/kg)
Trial: 16845627
Drug: Aventis Pasteur
RxNorm normalized name: Human fibrinogen concentrate, pasteurized
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aventis Pasteur smallpox vaccine
Trial: 12600796
Drug: PGE(2) (3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE(2) (3, 6, and 12 nmol/ml)
Trial: 12600796
Drug: ATP (9000,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATP (9000, 18,000, and 36,000 nmol/ml)
Trial: 12600796
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Bk (92 nmol), 5‐HT (156 nmol), His (140 nmol), and PGE(2) (1.95 nmol)
Trial: 11672513
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + IFN (COPP: cyclophosphamide, vincristine, prednisone, procarbazine)
Trial: 7989949
Drug: High-dose interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose interleukin-2 (IL-2) (720,000 IU/kg) every 8 hours
Trial: 3068855
Drug: Chlorproguanil (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorproguanil (1.2 mg/kg) and dapsone (1.2 or 2.4 mg/kg)
Trial: 3068855
Drug: Pyrimethamine (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrimethamine (1.2 mg/kg) and sulfadoxine (24 mg/kg)
Trial: 28133919
Drug: Ocriplasmin (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocriplasmin (125 μg intravitreal injection)
Trial: 28133919
Drug: Placebo (intravitreal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intravitreal injection)
Trial: 25821725
Drug: 10% KOH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% KOH solution
Trial: 22214282
Drug: SAL +
RxNorm normalized name: salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAL + LAC combination
Trial: 29796866
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg triamcinolone (1 cc)
Trial: 29796866
Drug: 10 cc
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 cc (15 μg/ml) oxygen‐ozone (O2‐O3)
Trial: 22950711
Drug: Placebo (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (90 mg/d)
Trial: 8107615
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg oral oestriol/day for 3 months
Trial: 28651442
Drug: BI 695502
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 695502 (1 mg/kg)
Trial: 28651442
Drug: US-approved Avastin
RxNorm normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: US-approved Avastin (1 mg/kg)
Trial: 28651442
Drug: EU-approved Avastin
RxNorm normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: EU-approved Avastin (1 mg/kg)
Trial: 23797426
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of ASA
Trial: 23797426
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of clopidogrel
Trial: 21102260
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m and carboplatin AUC 6 once every 3 weeks for up to 6 cycles with enzastaurin 1125 or 1200 mg loading dose followed by 500 mg daily until disease progression
Trial: 21102260
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m and carboplatin AUC 6 once every 3 weeks for up to 6 cycles without enzastaurin
Trial: 21102260
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m and carboplatin AUC 6 once every 3 weeks for up to 6 cycles
Trial: 18511306
Drug: Stimulant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant treatment (psychomotor stimulant)
Trial: 18511306
Drug: Normal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal treatment (ADHD group assessed once on normal treatment)
Trial: 18511306
Drug: Withdrawal from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal from treatment (ADHD group assessed after withdrawing from treatment for at least one week)
Trial: 16328487
Drug: Group III
RxNorm normalized name: Corticosteroids, potent (group III)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III (moderate/severe nonproliferative DR with laser treatment)
Trial: 16328487
Drug: Group IV
RxNorm normalized name: Corticosteroids, very potent (group IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group IV (proliferative DR with laser treatment)
Trial: 14996265
Drug: Intravenous anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anaesthesia with ketamine and propofol (group P)